Q32 Bio (QTTB) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Market overview and opportunity

• Alopecia areata market is growing rapidly, with JAK inhibitors on track for $500M in 2026 U.S. net sales and 30–35% annual growth.

• U.S. patient population is estimated at 700,000–750,000, potentially reaching 800,000 in coming years.

• Addressable patients for advanced systemic therapy are estimated at 300,000, supporting a multibillion-dollar opportunity.

• JAK inhibitor penetration remains low, in the low double digits.

Clinical data and differentiation

• Lead asset bempikibart showed 40% mITT and 30% ITT SALT 20 response at 36 weeks, competitive with JAK efficacy but with a different safety profile.

• Bempikibart is a bifunctional antibody targeting IL-7 and TSLP, aiming to inhibit T effector and memory cells, differentiating it from other therapies.

• Safety profile is a key differentiator, with only 4% mild injection site reactions compared to higher rates and severity in competitors.

• Efficacy is in range or better than the most advanced biologic competitor, with lower adverse event rates.

Biomarker and patient response insights

• Responses observed in both IgE high and low patients, suggesting broad applicability.

• Post-JAK patients comprised 40% of the study, with non-responders often falling into this group; further biomarker and mechanistic data to be presented at EADV.

• Optional biopsies provided rich mechanistic data, supporting the drug’s mode of action.